Otsuka Announces First Collaboration Agreement to Bring the ABILIFY MYCITE® System to the US Market
Otsuka Pharmaceutical to Acquire Visterra
Otsuka and Lundbeck's Rxulti® (brexpiprazole) approved by the European Commission.
Rxulti® (brexpiprazole) has been approved for the treatment of schizophrenia in adults.
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
Otsuka And Proteus® Announce The First U.S. FDA Approval of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
FDA Accepts Otsuka’s Resubmission To Support A Regulatory Review Of Tolvaptan In The Treatment Of ADPKD